Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 71

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 71
---
 as a Cayman Islands exempted company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. OmnigenicsAI Corp89 Nexus Way
Camana Bay
Grand Cayman, KYI -9009
Cayman Islands OmnigenicsAI Corp is a newly incorporated Cayman Islands exempted company and was incorporated for the purpose of making acquisitions and investments, with the objective of acting as the publicly traded holding company for its subsidiaries. OmnigenicsAI is an artificial intelligence -drivengenomics company which aims to provide reliable biological data with a focus on early disease detection and health management. In addition, it aims to use diverse genomic technologies to provide personalized healthcare and tests which support a broad range of health conditions. Heritas Merger Sub Limited89 Nexus Way
Camana Bay
Grand Cayman, KYI -9009
Cayman Islands Heritas Merger Sub Limited is a newly incorporated Cayman Islands exempted company and a direct wholly owned subsidiary of OmnigenicsAI. Merger Sub was formed solely in contemplation of the Business Combination, has not commenced any operations, has only nominal assets and no liabilities or continent liabilities, nor any outstanding commitments other than in connection with the Business Combination. The Business Combination Pursuant to the Business Combination Agreement, APx, OmnigenicsAI, and Merger Sub will enter into the Business Combination, pursuant to which, among other things, (i) Merger Sub shall merge with and into SPAC, with SPAC being the surviving company and remaining as a wholly -ownedsubsidiary of the Company, and (ii) all SPAC Ordinary Shares and Public Warrants will be converted or exchanged into the right to receive the Merger Consideration. In connection with the closing of the transactions contemplated by the Transaction Documents, including the Transactions, each of APx, Theo and OmnigenicsAI has entered into the Backstop Agreement, agreeing, severally but not jointly, to provide the funding of certain amounts as set forth therein. For more information, see the section entitled “ The Business Combination Agreement.” 1

Equity Ownership and Dilution following the Business Combinations The following table presents the net tangible book value per share at various redemption levels assuming various sources of material probable dilution (but excluding the effects of the Business Combination transaction itself and including the effects of the contribution of cash by Theo and issuance of Company Shares in consideration thereof pursuant to the Back